Company intelligence / Profile preview
Mesoblast Ltd
Melbourne, Victoria, Australiamesoblast.com ↗
- Ownership
- Public · MESO
- Employees
- ~73
- Development stage
- Commercial
01
Overview
Mesoblast has developed the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease. Its pipeline includes late-stage clinical candidates targeting severe inflammatory diseases, heart failure, ARDS due to COVID‑19, and chronic low back pain. The company’s proprietary allogeneic cellular medicines are designed for scalable manufacturing and global distribution. Strategic partnerships support commercialization in major markets including Japan, China, Europe, and Latin America[1][2][3].
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularImmunologyNeurology
- Modalities
- Allogeneic mesenchymal lineage cell therapy (mesenchymal stromal cells/precursor cells)Cellular medicines
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
Request access →03
Partnerships
Grünenthal GmBH (Europe/Latin America – MPC‑06‑ID)JCR Pharmaceuticals Co. Ltd. (Japan – GVHD/wound healing)Tasly Pharmaceutical Group (China – cardiovascular products)Takeda Pharmaceutical Co./TiGenix NVLonza Group for manufacturing[4]
04
Financials
- Market cap
- $2.1B
- Total revenue
- $34.5M
- Enterprise value
- $2.2B
Beyond the preview
Go deeper on Mesoblast Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mesoblast Ltd.